Characterization of Ganstigmine metabolites in hepatocytes by low‐ and high‐resolution mass spectrometry coupled with liquid chromatography
- 23 June 2003
- journal article
- research article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 17 (15) , 1691-1698
Abstract
In order to deepen the understanding of the metabolism of Ganstigmine, a new acetylcholinesterase inhibitor under evaluation for the treatment of Alzheimer's disease, samples obtained by incubating the drug with female rat hepatocytes were investigated by low‐resolution liquid chromatography/tandem mass spectrometry (LC/MS/MS). The results confirmed the formation of most of the phase I metabolites already demonstrated, but also three new species. The combination of high‐resolution quadrupole time‐of‐flight (Q‐TOF) LC/MS and LC/MS/MS measurements, and the evaluation of the more reasonable metabolic routes, allowed the identification of the new metabolites as Geneseroline‐glucuronide and oxidized and rearranged Ganstigmine. Analogous investigations were made using hepatocytes from male rat and dog, and both gender monkeys and humans, to compare the metabolic patterns. The results did not indicate substantial differences in terms of numbers and abundances of detected metabolites among the considered species, and also between male and female hepatocytes within each species. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 8 references indexed in Scilit:
- Tandem mass spectrometric accurate mass performance of time‐of‐flight and Fourier transform ion cyclotron resonance mass spectrometry: a case study with pyridine derivativesRapid Communications in Mass Spectrometry, 2001
- Determination of purine compounds in carotid artery plaque by liquid chromatography electrospray ionization tandem mass spectrometryJournal of Mass Spectrometry, 2001
- Biochemical and Neurobehavioral Profile of CHF2819, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer's DiseaseThe Journal of Pharmacology and Experimental Therapeutics, 2000
- In Vitro Metabolism of the HIV-1 Protease Inhibitor ABT-378: Species Comparison and Metabolite IdentificationDrug Metabolism and Disposition, 1999
- Solution‐ and Solid‐state Structures of the (—)‐n‐Heptylcarbamate of Geneseroline and Its Hydrochloride SaltJournal of Pharmaceutical Sciences, 1995
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991
- Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severityAnnals of Neurology, 1990
- Pathological changes in the nucleus of meynert in Alzheimer's and Parkinson's diseasesJournal of the Neurological Sciences, 1983